|
Combined use of albumin and neutrophil-to-lymphocyte ratio as new prognostic and predictive factor in patients with poorly differentiated neuroendocrine carcinomas. |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - I have a patent for a method for the identification of gene panels optimal for TMB estimation (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Ipsen; Novartis |
|
|
Travel, Accommodations, Expenses - Ipsen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Roche |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
|
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Incyte; Inivata; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda |
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Lilly; MSD Oncology; SERVIER |
Consulting or Advisory Role - Lilly; MSD Oncology |
|
Travel, Accommodations, Expenses - Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Ignyta; Incyte; Nerviano Medical Sciences; Octimet; Pierre Fabre; Roche; Sanofi; Teofarma |
Speakers' Bureau - Menarini |
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst) |
|
|
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD |
|
|
Consulting or Advisory Role - Ipsen; Italfarmaco; Novartis; Pfizer |
Research Funding - Novartis; Pfizer/Ipsen |